Radiation therapy is a staple approach for cancer treatment, whereas radioresistance of cancer cells remains a substantial clinical problem. In response to ionizing radiation (IR) induced DNA damage, cancer cells can sustain/activate pro-survival signaling pathways, leading to apoptotic resistance and induction of cell cycle checkpoint/DNA repair. Previous studies show that Rac1 GTPase is overexpressed/hyperactivated in breast cancer cells and is associated with poor prognosis. Studies from our laboratory reveal that Rac1 activity is necessary for G2/M checkpoint activation and cell survival in response to IR exposure of breast and pancreatic cancer cells. In this study, we investigated the effect of Rac1 on the survival of breast cancer cells treated with hyperfractionated radiation (HFR), which is used clinically for cancer treatment. Results in this report indicate that Rac1 protein expression is increased in the breast cancer cells that survived HFR compared with parental cells. Furthermore, this increase of Rac1 is associated with enhanced activities of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and nuclear factor-κB (NF-κB) signaling pathways and increased levels of anti-apoptotic protein Bcl-xL and Mcl-1, which are downstream targets of ERK1/2 and NF-κB signaling pathways. Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate that Rac1 inhibition decreases the phosphorylation of ERK1/2 and inhibitory κBα (IκBα), as well as the levels of Bcl-xL and Mcl-1 protein in the HFR-selected breast cancer cells. Moreover, inhibition of Rac1 using either small molecule inhibitor or dominant-negative N17Rac1 abrogates clonogenic survival of HFR-selected breast cancer cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apoptosis induction. Collectively, results in this report suggest that Rac1 signaling is essential for the survival of breast cancer cells subjected to HFR and implicate Rac1 in radioresistance of breast cancer cells. These studies also provide the basis to explore Rac1 as a therapeutic target for radioresistant breast cancer cells.
INTRODUCTION
Radiation therapy (RT) is routinely used for breast cancer treatment. 1 Although ionizing radiation (IR) delivered by RT causes DNA damage in cancer cells that can lead to cell death, radioresistance (primary or acquired) remains a major problem in clinic. 2 Thus, there is a need to improve our understanding of the mechanisms that protect cancer cells from RT-induced cytotoxicity.
In response to IR, cancer cells activate several mechanisms that promote DNA repair and survival. 3 Among these, activation of ataxia telangiectasia-mutated (ATM)/ATM-and Rad3-related (ATR), phosphatidylinositol 3 kinase (PI3K)/AKT and mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathways are commonly observed following IR treatment of cancer cells. 3, 4 Although the ATM/ATR signaling pathway has an essential role in cell cycle checkpoint activation that leads to cell cycle arrest and DNA repair, 5 PI3K/AKT and MEK/ ERK signaling pathways promote survival through upregulation of anti-apoptotic factors (for example, Bcl-2/Bcl-xL/Mcl-1) and inhibition of pro-apoptotic factors (for example, Bid/Bad). 3, 4 The nuclear factor-κB (NF-κB) signaling pathway has an important role in cell proliferation and survival in the inflammatory response. 6 When inactive, NF-κB is sequestered by the inhibitory κB protein (IκB) in the cytoplasm. 6 Upon stimulation by inducers including radiation, IκB becomes phosphorylated by IκK kinases and subjected to proteasomal degradation. 6 This releases the sequestered NF-κB, allowing it to translocate into the nucleus and induce changes in targeted gene expression levels. 6 In addition, IR-induced ATM and reactive oxygen species can further enhance activation of the NF-κB pathway. 7 The best validated NF-κB gene targets include Bcl-2, Bcl-xL and Mcl-1, which are members of the anti-apoptotic Bcl-2 family. 8 Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of Rho family GTPases, has important roles in cell migration and survival. 9 Rac1 exists in either an active guanosine triphosphate (GTP)-bound state or inactive guanosine diphosphate (GDP)-bound state. 10 Rac1 is activated by its guanine nucleotide exchange factors (GEFs), which accelerate GDP to GTP exchange, and inhibited by its GTPase-activating proteins (GAPs), which stimulate GTP hydrolysis. 10 In its active state, Rac1 interacts with downstream effectors to activate numerous signaling pathways. 11, 12 Rac1 has been reported to activate ERK1/2 signaling via the p21-activated kinases 1 and 2 (PAK1/2), which phosphorylate Raf1 and MEK1 to facilitate the formation of the Raf/MEK/ERK complex. [13] [14] [15] Rac1 also interacts with PI3K to activate PI3K/AKT signaling 16, 17 and has an essential role in AKT activation following ultraviolet or sphingosine 1-phosphate treatment. 18, 19 Both AKT and ERK1/2 signaling pathways have been shown to promote survival after IR. 3, [20] [21] [22] [23] [24] [25] In addition, Rac1 is required for IR-induced reactive oxygen species production and ATM activation, 3, 26, 27 which activates the NF-κB signaling pathway. 28 Rac1 and its modulators (GEFs/GAPs) are implicated in cancer development, invasion and metastasis. 10 Overexpression/ hyperactivity of Rac1 has been associated with cancer therapy resistance. [29] [30] [31] For instance, aberrant Rac1 amplification/activation is linked to chemo/radioresistance of head and neck squamous cell carcinomas and glioblastoma cells, and the head and neck squamous cell carcinoma cells resistant to cisplatin or radiation displayed an increased Rac1 expression, activity and translocation to the nuclei. [31] [32] [33] [34] Further, inhibition of Rac1 using either pharmacological inhibitor or small interfering RNA restores the chemo/radio sensitivity of these cancer cells. 31, 34 Rac1 is also shown to have an essential role in the resistance of breast cancer cells to trastuzumab (anti-human epidermal growth factor receptor 2 (HER2) therapy) and this involves deletion of the phosphatase and tensin homolog (PTEN) and overexpression of the insulin-like growth factor-1 receptor. 35 Consistently, highthroughput RNA interference screens identify Rac1 amplification as one of the most biologically relevant mechanisms of anti-HER2 therapy resistance in breast cancer. 30 We recently reported a new Rac1 function in the regulation of the IR response of breast and pancreatic cancer cells. 26, 27 We show that Rac1 is rapidly activated by IR and is required for ATM/ATR activation and cell survival following IR. Similarly, other studies reported that Rac1 deficiency reduces DNA damage checkpoint response, DNA repair and survival after exposure to IR and ultraviolet radiation. 36 In this study, we investigated the role of Rac1 in the response of human breast cancer cells to hyperfractionated radiation (HFR), a protocol currently used for cancer therapy. Results in this report show that Rac1 signaling is required for the survival of breast cancer cells following HFR, suggesting a clinical potential of targeting Rac1 for radiosensitization of breast cancer cells.
RESULTS

Rac1 is overexpressed in human breast cancer cells
We analyzed Rac1 protein expression in a panel of normal and malignant breast cell lines. The genetic characteristics of these cell lines were previously reported and are summarized in Supplementary Table S1 . [37] [38] [39] As shown in Figure 1a , immunoblotting detected an average of 2-5-fold higher levels of Rac1 in the breast cancer cell lines compared with 76N normal human mammary epithelial (HME) cells. To assess whether Rac1 overexpression observed in the breast cancer cell lines translates to clinical samples, we assessed Rac1 expression by immunohistochemistry (IHC) in a tissue microarray (TMA), which consists of 33 cases of human normal breast/benign tumor tissues (NT) and 36 cases of human malignant breast tumor tissues. As shown in Figures 1b and c, IHC detected specific immunostaining for Rac1 with moderate to strong levels in the majority of breast tumor tissues, whereas the majority of NT samples were negative or weakly positive for Rac1 staining. Among the TMA samples, 64% (23/36) of breast tumors had strong to moderately high levels of Rac1 expression, whereas weak to no Rac1 expression was observed in 58% (19/33) of NT samples. The analysis also showed that 18% (6/33) of NT samples had strong to moderately high levels of Rac1 expression. Overall, IHC analysis indicates a significantly higher level of Rac1 expression in breast tumor samples compared with NT samples (P o0.001).
Rac1 is activated in breast cancer cells responding to IR
We have previously shown that IR activates Rac1 in MCF-7 cells. 26 We therefore tested whether IR causes a similar effect on other normal and cancerous mammary cell lines. As shown in Figure 2 , Rac1 activity (Rac1-GTP) increased approximately fourfold in ZR-75-1, MDA-MB-231 and BT-474 breast cancer cells within 15 min following IR exposure. However, no increase in Rac1 activity was detected in 76N HME cells after IR.
Rac1 expression is increased in the breast cancer cells that survived HFR As aberrant amplification/activation of Rac1 is associated with poor prognosis of breast cancer, 10, 40 we assessed the effect of HFR on Rac1 and its downstream pro-survival signaling pathways in breast cancer cells. For this study, MDA-MB-231 and MCF-7 cells were subjected to a clinical protocol of HFR (50-Gy in 2.5-Gy daily) and the surviving cells were selected following treatment ( Figure 3a) .
As shown in Figure 3a , MDA-MB-231 and MCF-7 cells that survived the HFR (RT) were morphologically different from their corresponding wild-type (WT) parental cells. These cells appeared rounded-up and less adherent to substratum compared with parental cells. We next analyzed the Rac1 protein level in the HFRtreated cells. As shown in Figure 3b , when compared with their parental cells, approximate 10-and 3-fold increases in Rac1 protein level were detected in MDA-MB-231-RT and MCF-7-RT cells, respectively.
To investigate the mechanism by which Rac1 expression is increased in the breast cancer cells treated with HFR, Rac1 mRNA levels in WT and RT cells were examined by reverse transcriptase-PCR (RT-PCR). As shown in Figure 3c , both MDA-MB-231-RT and MCF-7-RT cells expressed the same level of Rac1 mRNA as their respective parental cells. Thus, the increase in Rac1 protein expression in the HFR-treated cells apparently involves a posttranscriptional mechanism.
Breast cancer cells that survived HFR exhibit altered pro-survival signaling properties compared with their parental cells As the breast cancer cells treated with HFR survived 50-Gy fractionated radiation delivered over 4 weeks, it is expected that substantial changes in biology occurred in these cells compared with their parental cells. Therefore, we compared activities and/or levels of several pro-survival signaling pathways in the HFRtreated cells with the corresponding parental cells. As shown in Figure 3d , AKT phosphorylation was unexpectedly decreased in both MDA-MB-231-RT and MCF-7-RT cells. Furthermore, AKT protein level was also markedly decreased in MDA-MB-231-RT cells compared with MDA-MB-231-WT cells, whereas it remained unchanged in MCF-7-RT cells relative to MCF-7-WT cells. In contrast, phosphorylation of ERK1/2 and IκB, indicative of activation of the ERK1/2 and NF-κB signaling pathways, were markedly increased in both MDA-MB-231-RT and MCF-7-RT cells relative to their respective parental cells (Figure 3d ).
To determine the biological impact of the upregulation in ERK1/2 and NF-κB signaling pathways in the HFR-treated breast cancer cells, we analyzed the downstream targets of these signaling pathways. As shown in Figure 3d , immunoblotting indicates notable increases in anti-apoptotic proteins Bcl-xL and Mcl-1 L in both MDA-MB-231-RT and MCF-7-RT cells compared with their parental cells. In contrast, no difference in Bcl-2 protein levels were observed between the HFR-treated cells and untreated cells. These results indicate augmentation of pro-survival signaling activities in the breast cancer cells that survived HFR.
As both ERK1/2 and NF-κB signalings can promote survival and proliferation, we compared growth kinetics of HFR-treated cells with their parental cells. Results in Figure 3e show that both MDA-MB-231-RT and MCF-7-RT cells grew significantly slower than their parental cells.
We next compared the HFR-treated cells and untreated cells for their cell cycle response to IR. As shown in Supplementary Figure S1 , both MDA-MB-231-RT and MCF-7-RT cells, either with or Collectively, these results indicate that the HFR-selected cells adopted many changes in biological characteristics in order to survive the cytotoxicity induced by HFR.
Inhibition of Rac1 abrogates upregulation of the pro-survival signaling pathways in the HFR-selected breast cancer cells As shown in Figures 3b-d , HFR treatment of breast cancer cells resulted in an upregulation of Rac1 expression and a concomitant increase in activities of ERK1/2 and NF-κB pro-survival signaling pathways. We therefore assessed the effect of Rac1 on these signalings.
We first tested the effect of Rac1 inhibition by NSC23766 on these signaling pathways and their downstream targets, the Bcl-2 family members. We previously demonstrated that incubation with NSC23766 abrogates IR-induced Rac1 activation in MCF-7 cells. 26 Similarly, incubation with NSC23766 abolished Rac1 activation after IR in MDA-MB-231-RT cells ( Figure 4a ).
As shown in Figure 4b , IR exposure induced noticeable increases in phosphorylation of ERK1/2 and IκBα in both MDA-MB-231-RT and MCF-7-RT cells, whereas the increases were completely abrogated by incubation with Rac1 inhibitor NSC23766. Rac1 inhibition by NSC23766 also diminished the basal phosphorylations of ERK1/2 and IκBα in un-irradiated MDA-MB-231-RT cells (Figure 4b ).
We next examined the effect of Rac1 on the expression of Bcl-xL, Mcl-1 L and Bcl-2, which are downstream targets of the ERK1/2 and NF-κB pathways. As shown in Figure 4c , IR exposure resulted in increased protein expression of Bcl-xL and Mcl-1 L in both MDA-MB-231-RT and MCF-7-RT cells. However, these IR effects were abolished in both cell lines by the presence of Rac1 inhibition. Rac1 inhibition also decreased the basal protein expression of Bcl-xL and Mcl-1 L in un-irradiated MDA-MB-231-RT cells. In contrast, neither IR nor Rac1 inhibition had any detectable effect on the steady-state level of Bcl-2 protein in both MDA-MB-231-RT and MCF-7-RT cells.
In summary, these results suggest that Rac1 is required for the maintenance of hyperactive pro-survival pathways in the breast cancer cells selected by HFR.
Ectopic expression of dominant-negative N17Rac1 mutant diminishes pro-survival signaling pathways in the HFR-selected breast cancer cells Using an adenoviral vector expressing N17Rac1, a dominantnegative Rac1 mutant, 41 we tested the effect of Rac1 on the prosurvival signaling pathways in MDA-MB-231-RT and MCF-7-RT cells in the presence or absence of IR. As shown in Figure 5a , immunoblotting detected the ectopically expressed N17Rac1, which migrates slightly slower than the endogenous wild-type Rac1. 26, 27 Results in Figure 5a showed that the IR-induced increases in ERK1/2 and IκBα phosphorylation in MDA-MB-231-RT and MCF-7-RT cells were completely blocked by the expression of N17Rac1 mutant.
We next examined the effect of N17Rac1 mutant on downstream targets of ERK1/2 and NF-κB signaling pathways. As shown in Figure 5b , whereas IR exposure resulted in an increase in protein levels of Bcl-xL and Mcl-1 L in the control-transduced MDA-MB-231-RT and MCF-7-RT cells, this effect was abrogated by the expression of N17Rac1. In addition, in the absence of IR, N17Rac1 expression also resulted in decreases in protein levels of Bcl-xL and Mcl-1 L in MDA-MB-231-RT and MCF-7-RT cells (Figure 5b) . Consistent with the effect observed with the Rac1 inhibitor NSC23766, N17Rac1 expression also had little effect on the steady-state level of Bcl-2.
Inhibition of Rac1 blocks survival of the HFR-selected breast cancer cells but not normal mammary epithelial cells As inhibition of Rac1 either by NSC23766 or by N17Rac1 mutant resulted in suppression of pro-survival signaling activities (Figures 4 and 5) , we examined the effect of Rac1 inhibition on cell survival, in the presence or absence of IR. As shown in Figure 6a , whereas IR itself had little effect on the morphology of MDA-MB-231-RT cells, inhibition of Rac1 by NSC23766 caused 450% of cells to round-up and shrink, which is indicative of cytotoxicity. 42 IR exposure in the presence of NSC23766 resulted in a further increase in cytotoxicity compared with the cells treated with NSC23766 alone, as 490% of the cells treated with both IR and NSC23766 rounded-up and detached from substratum (Figure 6a ), indicating a synergistic cytotoxic effect.
We verified the cytotoxic effect of Rac1 inhibition using a clonogenic assay. As shown in Figures 6b and c, GAPDH was assessed as a protein loading control. (e) The indicated cells were analyzed for growth kinetics using AlamarBlue assay, as described previously. 59 At indicated time points, 10% of AlamarBlue reagent was added to the cells, incubated for 130 min and measured for fluorescence intensity using a SpectraMax M5 plate reader (Molecular Devices, Inc., Sunnyvale, CA, USA) at ex/em 544/590 nm. We have previously shown that Rac1 inhibition alone has little effect on the survival of wild-type MCF-7 cells, while it synergized with IR, abrogating clonogenic survival of MCF-7-WT cells after IR. 26 We therefore tested whether Rac1 inhibition affects clonogenic survival of MDA-MB-231-WT cells. As shown in Supplementary Figure S2 , Rac1 inhibition by NSC23766 resulted in a noticeable but statistically insignificant reduction in the number of colonies formed by these cells. Consistent with the result obtained from MCF-7-WT cells, 26 inhibition of Rac1 by NSC23766 also abrogated clonogenic survival of MDA-MB-231-WT cells after IR (Supplementary Figure S2) . For a comparison, we also tested the effect of Rac1 inhibition on survival of 76N human normal mammary epithelial cells, which expressed lower Rac1 levels compared with MCF-7-WT and MDA-MB-231-WT cells (Figure 1a) . Results in Supplementary Figure S3 showed that, although IR resulted in a dose-dependent decrease in survival of 76N cells, inhibition of Rac1 had no additional effect on the survival of these cells following IR.
To verify the effect of Rac1 inhibition on 76N cell survival after IR, we analyzed the phosphorylation of ERK1/2 and IκB in these cells. As shown in Supplementary Figure S4a N17Rac1 on un-irradiated MDA-MB-231-RT cells was statistically significant (Figure 6d , 0-Gy, P = 0.029, n = 4), its effect on MCF-7-RT cells was insignificant (Figure 6e , 0-Gy, P = 0.343, n = 4). It should be noted that the size of colonies formed by the N17Rac1 expressing cells, in both MDA-MB-231-RT or MCF-7-RT cells, were smaller than their corresponding control cells (Figures 6d and e) .
Collectively, results of these studies suggest that Rac1-mediated pro-survival signalings are essential for the survival of breast cancer cells in response to HFR treatment. In addition, the HFRselected breast cancer cells, which express a higher level of Rac1 than their parental cells, are more sensitive to Rac1 inhibition than their parental controls, suggesting an addiction of the HFR-treated cells to Rac1 signaling for survival.
Rac1 inhibition induces apoptosis in the HFR-selected breast cancer cells To investigate the mechanisms involved in the decrease in survival of the HFR-selected breast cancer cells by Rac1 inhibition, we assessed the integrity of poly(ADP-ribose) polymerase (PARP) in these cells in the presence or absence of Rac1 inhibition. Cleavage of PARP is a hallmark of apoptosis and it occurs during the execution phase of programmed cell death. 43 As shown in Figure 7a , in the absence of NSC23766, IR exposure had no detectable effect on the levels of intact PARP in both MDA-MB-231-RT and MCF-7-RT cells, determined at 48 h post IR. In contrast, inhibition of Rac1 by NSC23766 alone resulted in a marked decrease in the level of intact PARP in both MDA-MB-231-RT and MCF-7-RT cells. In addition, IR exposure in the presence of Rac1 inhibition eliminated the residual intact PARP that was present in the cells treated with NSC23766 alone (Figure 7a,  lanes 4 vs 3) .
To verify the effect of Rac1 inhibition on PARP, cells were transduced with Ad.N17Rac1 or Ad.Control and exposed to IR. As shown in Figure 7b , transduction with Ad.N17Rac1 resulted in a marked decrease in levels of intact PARP in both MDA-MB-231-RT and MCF-7-RT cells compared with the control-transduced cells (lanes 3 vs 1) . Furthermore, IR exposure of N17Rac1 expressing cells resulted in a further decrease of intact PARP relative to the un-irradiated N17Rac1-transduced cells (Figure 7b, lanes 4 vs 3) .
Collectively, these studies indicate that inhibition of Rac1 in the HFR-selected breast cancer cells results in apoptosis induction.
DISCUSSION
Hyperactive Rac1 signaling has been implicated in cancer development and is associated with poor prognosis. 40, 44, 45 In this study, we observe a significant upregulation of Rac1 protein expression in cancerous versus normal HME cells and tissues (see Figure 1) . Furthermore, IR induces a rapid Rac1 activation in breast cancer cells and the breast cancer cells that survived the clinical HFR protocol reveal an increase in Rac1 protein expression, which is associated with an overall increase in pro-survival signaling activities (Figures 2 and 3) . In addition, the HFRselected cells display very different cell cycle distribution profiles compared with their parental cells, with or without IR, and the changes are apparently cell type specific (see Supplementary Figure S1 ). Moreover, the HFR-selected cells grow significantly slower than parental cells (Figure 3e ). These results indicate that the HFR-selected cells have gone through adaptive changes to resist the cytotoxic pressure generated by HFR and suggest an involvement of Rac1 in the survival of the breast cancer cells treated with HFR.
Activation of AKT, ERK1/2 and NF-κB signaling pathways following IR has been implicated in survival and radioresistance. 28, 46, 47 Rac1 is required for PI3K/AKT activation by lipopolysaccharide and MEK/ERK activation by 12-O-tetradecanoylphorbol-13-acetate. 48, 49 In addition, Rac1 is essential for activation of the NF-κB signaling pathway during inflammation and in the initiation of colorectal cancer that carries mutations in APC. 50, 51 These studies suggest that AKT, ERK1/2 and NF-κB pro-survival signalings are downstream targets of Rac1. Results in this report show that HFR results in increased Rac1 expression and increased phosphorylation of ERK1/2 and IκBα in the HFR-selected cells (see Figure 3d) . Furthermore, Rac1 inhibition abrogates the HFR-induced phosphorylation of ERK1/2 and IκBα, and the expression of downstream anti-apoptotic proteins Bcl-xL and Mcl-1 L (see Figures 4  and 5) . These results suggest an involvement of Rac1-regulated ERK1/2 and NF-κB signaling pathways in the survival of breast cancer cells following HFR.
Our previous studies indicate that inhibition of Rac1 in wild-type breast and pancreatic cancer cells blocks survival of irradiated cells, whereas it has little effect on the survival of non-irradiated cells. 26, 27 However, results of this study indicate that the HFRselected breast cancer cells exhibit sensitivity to Rac1 inhibition in the absence of IR (see Figures 6 and 7) . Biochemical analyses indicate that Rac1 inhibition alone reduces phosphorylation of ERK1/2 and IκBα, as well as levels of anti-apoptotic proteins Bcl-xL and Mcl-1 L in the non-irradiated HFR-selected cells (see Figures 4 and 5) . In contrast, Rac1 inhibition by NSC23766 does not suppress the survival of normal 76N HME cells that express very little Rac1, whether with/without IR (Supplementary Figure S3) . Consistently, inhibition of Rac1 also does not decrease phosphorylation of ERK1/2 or IκBα in 76N cells treated with/without IR (Supplementary Figure S4) . These results suggest a sequential increase in dependency on Rac1 for survival from normal HME cells → primary breast cancer cells → HFR-selected cells.
Both Bcl-2 and Bcl-xL have been shown to have critical roles in anticancer therapeutic resistance. 52, 53 Although the two proteins share 45% sequence identity, 54 studies demonstrate some differences in their anti-apoptotic functions responding to stimuli. For instance, Fiebig et al. 54 show that Bcl-2 overexpression blocks the apoptosis induced by ceramide or thapsigargin, but has no effect on doxorubicin-or TNFα-induced apoptosis. On the other hand, Bcl-xL overexpression can block the apoptosis induced by all four stimuli. 54 In this study, we show that Bcl-xL expression is upregulated following HFR, whereas Bcl-2 level is unaffected by HFR (Figure 3d and Bcl-xL, Rac1 is apparently required for the upregulation of these proteins after HFR or IR. Future studies are needed to elucidate the molecular pathways that upregulate these antiapoptotic molecules in response to HFR.
RT is a staple cancer treatment approach, whereas its efficacy is still limited by radioresistance. Although RT induces cytotoxicity in cancer cells, it concurrently activates multiple pro-survival signaling pathways, 3, 4 which can act conjointly to reduce the magnitude of radiation-induced cytotoxicity and promote radioresistance. Results in this report provide evidence supporting a key role for Rac1 in the survival of breast cancer cells following HFR. Studies to explore the clinical potential of targeting Rac1 signaling for radiosensitization of cancer cells are currently underway and will be reported in due course. 
MATERIALS AND METHODS
TMA and immunohistochemistry
The clinical specimen for IHC was a commercial TMA (BR723) (US Biomax, Rockville, MD, USA). The TMA included 33 cases of human breast normal or benign tumor tissues (NT) and 36 cases of human malignant breast tumor tissues at various stages. The TMA was analyzed for Rac1 expression by IHC, as described previously, 57,58 using a Rac1-specific antibody (PA1-091) at 1:400 dilution. The Rac1 immunostaining intensity was evaluated by a UNMC pathologist who was blinded to the clinical information.
Rac1 activity assay
Rac1 activity was assayed using a Rac1 assay kit (Upstate Biotechnology, Lake Placid, NY, USA), as described in our previous studies. 26, 27 RT-PCR analysis Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and analyzed for human Rac1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA by real-time RT-PCR using the RT 2 RealTime Syber Green RT-PCR system (SuperArray Bioscience, Frederick, MD, USA). The relative Rac1 mRNA expression was adjusted with GAPDH mRNA levels. The PCR primer sequences are included in Supplementary Materials.
Growth kinetics
Growth kinetics was determined using AlamarBlue assay (Life Technologies, Carlsbad, CA, USA) as described previously. 59 Cell cycle analysis Fluorescence-activated cell sorting was performed as described previously. 22 
Adenoviral vectors and adenoviral infections
Recombinant adenovirus N17Rac1 (Ad.N17Rac1) and dl312 (Ad.Control) were kindly provided by Dr Toren Finkel (NIH, Bethesda, MD, USA). In Ad. N17Rac1, the Rac1 complementary DNA contains a Ser to Asp substitution at position 17 and functions as a dominant-negative mutant. 60 Adenoviral infection was performed as described previously. 
Clonogenic survival assay
Clonogenic assay was performed and quantified as described previously. 26, 27, 62 Statistical analysis
Composite-score was evaluated by multiplying the values of the IHCstaining intensity and the percentage of immunoreactive cells. 57, 58 The data are shown as mean ± s.d. P-values were determined using Student's t-test and P ⩽ 0.05 was considered as significant. All statistical analyses were done using SigmaPlot (Systat Software Inc., San Jose, CA, USA).
